Best Genomics Companies in Belgium
The 64 best Genomics companies in Belgium in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Biocartis.
- Genomics Market Size to Grow by USD 18,244.34 million from 2022 to 202
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Belgium
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Biocartis Developer of molecular assays for the detection of various diseases | $305M | 45 mo ago | 43 | 2007 | — | DrupalApple iCloud MailMicrosoft 365+15 | 225 patents Advanced nucleic acid extraction and multiplex PCR diagnostics for cancer biomarker detection | 2 job openings · 1 launch |
| 2 | Devgen An agritech company developing hybrid seeds and crop protection solutions | $71M | 65 mo ago | 35 | 1997 | Bipin Solanki CEO | — | 461 patents RNA-based gene silencing technologies for insect and plant pest control. | — |
| 3 | ActoGeniX Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. | $57M | 158 mo ago | 5 | 2006 | — | — | 145 patents Patents concentrated in health & consumer products | — |
| 4 | OncoDNA Theranostic and genomic company for precision medicine in oncology | $45M | 31 mo ago | 37 37 → 46 (+24%) | 2012 | — | Cart FunctionalityWordPressApple iCloud Mail+38 | 35 patents Personalized cancer neoantigen vaccines and tumor sequencing for individualized immunotherapy | — |
| 5 | Volition Developer of cancer diagnostic tests | $40M | 2 mo ago | 104 | 1995 | Cameron Reynolds CEO | WordPressMySQLPHP+26 | — | 1 launch · 1 partnership |
| 6 | OncoMethylome Diagnostics for early detection of cancer | $34M | 247 mo ago | 3 | 2003 | — | — | — | — |
| 7 | Epics therapeutics Developer of small molecules to treat cancer | $25M | 90 mo ago | 30 30 → 30 (+0%) | 2018 | Jean Combalbert Founder & CEO | — | 44 patents Small-molecule METTL3 methyltransferase inhibitors for oncology | — |
| 8 | MyCartis Provider of bio-marker discovery platform for immunodiagnostics | $20M | 141 mo ago | 2 | 2006 | — | — | 127 patents Encoded microcarrier production and multiplexed bioassay platforms for high-throughput diagnostics | — |
| 9 | Aspect Analytics Developer of mass spectroscopy integrated bioinformatics software for molecular imaging | $12M | 9 mo ago | 2 | 2018 | Marc Claesen Co-Founder & CEO | WebflowGSAPHubSpot+16 | 4 patents Integrating and analyzing spatial multi-omics datasets for bioinformatics and biomedical research | — |
| 10 | Multiplicom Provider of molecular diagnostics assays for cancer and prenatal testing | $10M | 121 mo ago | 123 | 2011 | — | — | 48 patents Non‑invasive prenatal genetic testing, quantitative PCR assays, and transplant health monitoring | — |
| 11 | Cartagenia Software tools to visualize, assess and report clinical genetics data | $9M | 133 mo ago | 158 | 2008 | — | — | 10 patents Genomic data analysis and copy-number variation detection for cancer diagnostics | — |
| 12 | Diagenode Developer of portfolio of reagents and kits for epigenetics sequencing solutions | $8M | 81 mo ago | 99 99 → 125 (+26%) | 2003 | — | Cart FunctionalityPHPSalesforce+28 | 39 patents Patents concentrated in chemistry & materials | — |
| 13 | Trince Developer of cell transfection machinery | $5M | 54 mo ago | 3 | 2019 | Kevin Braeckmans Co-founder and CSO/CTO | WordPressMySQLPHP+19 | — | — |
| 14 | Biogazelle Transcriptomics-based diagnostics and therapeutics, and qPCR software. | $4M | 77 mo ago | 20 | 2007 | — | — | 5 patents Compact self-delivering oligonucleotide therapeutics for intracellular long non‑coding RNA targeting | — |
| 15 | Handl Therapeutics Developer of gene therapy to treat neurodegenerative diseases | $4M | 69 mo ago | 11 | 2019 | Michael Linden Founder | — | 2 patents Viral gene‑therapy vectors delivering therapeutic genes for Parkinson’s synucleinopathies | — |
| 16 | Hedera-22 Provider of services for computational analysis of biological data | $3M | 22 mo ago | 7 | 2015 | Pierre Tocquin Co-Founder | — | — | — |
| 17 | Perseus Biomics Provider of microbiome analysis technology for delivering precise microbiome profiles | $3M | 56 mo ago | 13 13 → 20 (+54%) | 2020 | — | Cart FunctionalitySquarespace CommerceSquarespace+15 | 7 patents Molecular diagnostic kits and genomic analysis tools for pathogen detection and imaging. | 1 partnership |
| 18 | BioStrand AI-powered biotherapeutic platform for antibody discovery | $2M | 49 mo ago | 7 | 2019 | Dirk Hyfte Co-Founder | HubSpot CMS HubMaterial Design Litecore-js+16 | 10 patents Bioinformatics data processing and storage systems for biological information | — |
| 19 | HistoGeneX Development of predictive biomarkers for cancer treatment through pathology and molecular biology | $2M | 144 mo ago | 150 | 2001 | — | — | 12 patents Impregnation methods and kits for preparing tissue samples for histopathology and molecular diagnostics | — |
| 20 | InSilico Genomics Bioinformatics solution for genomic data analysis | $2M | 159 mo ago | — | 2012 | David Y. Weiss Solís Co-Founder & CEO | — | — | — |
| 21 | Delphi Genetics Provider of research services in molecular biology, protein engineering, and antibody development | $1M | 119 mo ago | 85 | 2001 | — | — | 26 patents Engineered bacterial hosts and modified bacteriophages for recombinant protein/biomolecule production | — |
| 22 | Cell Matters CDMO focused on manufacturing of cell therapy products | $872K | 101 mo ago | 6 | 2017 | Delphine Connan Co-Founder | — | 10 patents Formulating cryopreservation solutions for preserving biological materials | — |
| 23 | DName-iT Provider of a sequence-based genetic testing platform | $631K | 35 mo ago | 1 | 2014 | Harry Cuppens Founder & CSO | — | 16 patents Biomolecular sample identification and nucleic acid analysis methods | — |
| 24 | ATLAS Neuroengineering Silicon based probes | $615K | 39 mo ago | — | 2012 | Arno Aarts Co-Founder & CEO | Microsoft ASP.NETBootstrapFancyBox+5 | 6 patents Implantable neural probes and hyperdrive systems for precise brain stimulation and recording | — |
| 25 | Progenus Provider of DNA analysis services and diagnostic kits | $395K | 29 mo ago | 14 14 → 14 (+0%) | 2001 | Robert Renaville Co-Founder & CEO | — | — | 3 launchs |
| 26 | Applied Maths Provider of software for bioinformatics, storage, and analysis of biological data | $303K | 137 mo ago | 28 | 1992 | Koen Janssens CEO | — | 6 patents Computational bioinformatics algorithms for sequence typing, phylogenetic trees, and consensus classification | — |
| 27 | DNAVision Provider of a wide range of genomic services to the pharmaceutical, food, and biotechnology industries | $294K | 88 mo ago | 5 | 2004 | Laurent Alexandre CEO | — | — | — |
| 28 | OhmX.bio Provider of research platform for research purposes | $201K | 81 mo ago | 4 | 2019 | Gerben Menschaert CSO & Co-Founder | WordPressMySQLPHP+34 | — | — |
| 29 | DNAlytics Provider of data-driven personalized medicine from R&D to market access | $110K | 128 mo ago | 7 | 2012 | Thibault Helleputte Founder & CEO | — | — | 2 launchs |
Top 12 Genomics companies in Belgium
#1
Public · Gembloux, Wallonia · founded 1995 · 104 employees$40Mraised▾
Developer of cancer diagnostic tests. The Nu-Q is used for early cancer diagnostics by detecting nucleosome markers of cancer and early-stage cells in the blood. It has also developed vet cancer screening tests.
- Mar 2026Post IPO$2.3M
- May 2025Post IPO$22.6M
- Mar 2024Post IPO$100K
- Dec 2023Post IPO$5.4M
#2
Series A · Genk, Flanders · founded 2018 · 2 employees$11.7Mraised▾
Aspect Analytics is the developer of mass spectroscopy integrated bioinformatics software for molecular imaging. Its services include bioinformatics, machine learning, AI and software engineering enables us to develop optimal data analysis strategies and MSI induces a true data deluge, requiring effective solutions for data management, storage, and analysis among others.
- Sep 2025Series A$11.7M
- Dec 2019Grant (prize money)—
#3
Public · Mechelen, Flanders · founded 2007 · 43 employees$305.3Mraised▾
Developer of molecular assays for the detection of various diseases. The company has developed its proprietary micro-technology platform that is based on integrated molecular and immunodiagnostics technology. It is used for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. It can also be used in the analysis of biomolecules associated with risk factors, early detection, staging, treatment selection, and monitoring of disease.
- Sep 2022Post IPO—
- May 2021Grant (prize money)$1.7M
- Dec 2020Post IPO$181.8M
- Sep 2020Grant (prize money)$1.4M
#4
Series C · Charleroi, Wallonia · founded 2012 · 37 employees$44.5Mraised▾
Theranostic and genomic company for precision medicine in oncology. The company's biomarker tests include OncoDEEP for precision medicine, OncoSELECT is a liquid biopsy solution for monitoring and therapeutics, and OncoFOLLOW is to monitor the progression of the tumor. Also has NGS interpretation platform OncoKDM for clinical information and biomarker test platform OncoSHARE.
#5
Series A · Belgium · founded 2015 · 7 employees$3.4Mraised▾
Hedera22 provides services for computational analysis of biological data. The company offers an integrative bioinformatics platform form for omic data analysis, data mining, sequencing for genomes, and transcriptomes. The company offers its software products PREDetector which helps in transcription factor-binding sites (TFBS) in bacterial genomes and PRESelector which is used for finding proteins, enzymes, and activities in organisms at a specific temperature and pH conditions.
- Aug 2024Series A$2.2M
- Sep 2020Seed$1.2M
#6
Acquired · Ghent, Flanders · founded 1997 · 35 employees$71Mraised▾
An agritech company developing hybrid seeds and crop protection solutions. It is a provider of biotechnology solutions for crop protection and environmental stress tolerance. They offer innovative products to the agricultural industry.
- Jan 2021Grant (prize money)$50.8K
- Feb 2007Post IPO$40.3M
- Jul 2000Post IPO$5.8M
- Oct 1999Post IPO$24.8M
#7
Acquired · Ghent, Flanders · founded 2006 · 5 employees$57.2Mraised▾
ActoGeniX is focused on the development and commercialization of ActoBiotics™, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases. Its proprietary TopAct platform developed enables the molecular engineering of food-grade microbes (lactococcus lactis) to generate biologically-contained ActoBiotics™ for in situ expression and secretion of novel biotherapeutic proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies to the oral and gastrointestinal tract. Its clinical stage products include AG013 which delivers a therapeutic peptide for the prevention and attenuation of oral mucositis, and AG014 which secretes anti-TNF-alpha Fab to treat inflammatory bowel disease with localized delivery minimizing systemic exposure. Acobiotics has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. The company has been acquired by Intrexon Corp. on Feb 2015.
- Apr 2013Series B$14M
- Feb 2009Series A$17.4M
- Jul 2007Grant (prize money)$4.2M
- Feb 2007Series A$25.8M
#8
Series B · Antwerp, Flanders · founded 2003 · 3 employees$33.9Mraised▾
OncoMethylome develops diagnostic tests for the early detection of cancer. It specializes in the development of assays based on methylation-specific PCR (PCR) that detects abnormal DNA methylation pathways. It is currently developing tests for prostate, bladder, colorectal, breast and cervical cancers.
- Nov 2005Series B$17.9M
- Jul 2003Series A$16M
#9
Series A · Charleroi, Wallonia · founded 2018 · 30 employees$24.7Mraised▾
Epics Therapeutics develops small molecules for treating cancer. The small molecules are used to target RNA epigenetic mechanisms to alter the structure and regulatory activities of RNA involved in cancer development.
- Dec 2018Series A$16.2M
- May 2018Seed$8.4M
#10
Acquired · Seraing, Wallonia · founded 2003 · 99 employees$8.5Mraised▾
Diagenode develops epigenetics solutions and services for life science research. Its flagship product IP-Star Compact is an automated bench-top solution for high-throughput epigenetic sequencing. It has automated protocols for chromatin immunoprecipitation (ChIP), methylated DNA immunoprecipitation (MeDIP), hydroxymethylated DNA immunoprecipitation (hMeDIP), methyl-binding domain protein capture assays (MethylCap), sequential ChIP (Re-ChIP), bisulfite conversion and DNA immunoprecipitation (RNA-IP). In addition, the company provides epigenetic sequencing services, reagents, kits, bioinformatics software associated with IP-Star.
- Sep 2019Grant (prize money)$117.7K
- Jul 2019Grant (prize money)$618.5K
- Jun 2019Grant (prize money)$287K
- Nov 2018Grant (prize money)$584.5K
#11
Deadpooled · Ghent, Flanders · founded 2006 · 2 employees$19.6Mraised▾
MyCartis provides solutions for a range of diseases in the fields of cardiovascular and women's health. The company's digital multiplex analysis platform called Evaluation is designed to analyze a range of protein and nucleic acid-based biomarkers. The company supports clinical research, pharmaceutical markets and researchers to understand the role of biomarkers in early disease and risk diagnosis and patient management.
- Sep 2014Series A$19.6M
#12
Acquired · Antwerp, Flanders · founded 2011 · 123 employees$10.4Mraised▾
Provider of molecular diagnostics assays for cancer and prenatal testing. Multiplicom develops, manufactures, and commercializes molecular diagnostic assays, provided as kits, which enable personalized medicine. It has CE-marked molecular diagnostic kits for the detection of BRCA-mutated ovarian and breast cancer, and for the prenatal detection of chromosomal abnormalities. In addition, the company also has a research-use only product range for somatic mutations, GIST tumors, chronic lymphocytic leukemia, hereditary colorectal cancer, and EGFR mutations.
- May 2016Grant (prize money)$2.1M
- Feb 2013Series B$7.4M
- Jun 2012Grant (prize money)$260K
- Apr 2011Series A$3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Belgium
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 628 Belgium-affiliated papers.
- Triphase136
- KU Leuven110
- Ghent University80
- Ghent University Hospital57
- Université Libre de Bruxelles34
- Gene1→19
- Genome4→15
- Identification (biology)1→7
- Cancer1→6
- Immune system1→6
- Disease1→21
- Cancer1→18
- Epigenetics1→8
- microRNA1→6
- Gut microbiome2→4
- Disease2→34
- Immune system1→13
- Inflammation1→6
- Genome2→6
- Gut microbiome1→4
Where bioinformatics is researched across Belgium
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.